From Academic Kits to Platform Licensing
Four products, expanding margin over time. Start with research kits, grow into pharma platforms and IP royalties.
Product roadmap
Sivoro Start
The research kit
Design complete, pending validationStrain + scaffold kit for academic labs. Drop-in replacement for standard PDMS protocols. Includes engineered N. crassa strain, H-tree scaffold masters, growth media, and protocols.
Price point
$2,500 / kit
$500 reagent kit (20 assays)
University research labs
Sivoro Organ
The pharma platform
PlannedOrgan-on-chip integration targeting liver, gut, and blood-brain barrier models. Includes custom strain engineering and multi-year service contracts for pharma R&D teams.
Price point
$50k–150k platform
$10k–30k annual service
Pharma R&D
Sivoro License
The IP stream
PlannedLicense Sivoro strain and valve IP to existing PDMS chip manufacturers. Non-exclusive royalties of 5–7%; exclusive arrangements at 10–12% plus upfront. Pure IP — lowest cost to deliver.
Price point
5–10% royalty
Exclusive: 10–12% + upfront
Microfluidics OEMs
Sivoro Dx
Research-use-only assay formats
Not a current programResearch-use-only diagnostic formats for academic and pharma R&D. Clinical pathways are a long-term possibility and not a current program.
Price point
Per-assay pricing
Subscription panel model
Research use only
TAM Expansion
Each product tier unlocks a larger addressable market. Figures below are internal estimates, not third-party market research.
The total microfluidics market is the ceiling; Sivoro's living-chip position enables entry across all three segments sequentially.
Internal estimates. Segment sizing is derived from published market reports and our own assumptions about addressable share; treat these as directional rather than researched figures.
Three revenue streams, expanding margin over time
Stream 1
Academic Kits
First post-validation stream
Sivoro Start kit: strain + scaffold + protocols. Recurring revenue from media replacements and strain upgrades.
$2,500 starter · $500 reagent kit (20 assays)
Stream 2
Pharma Platforms
Follows the kit
Sivoro Organ platform with organ-chip integration. Custom strain engineering + service contracts.
$50k–150k platform · $10k–30k annual service
Stream 3
IP Licensing
Follows the platform
License strain + valve IP to PDMS manufacturers. Pure IP — lowest cost to deliver.
Non-exclusive: 5–7% royalty · Exclusive: 10–12% + upfront
Modeled gross margins, pre-validation. The margin figures above (70%, 60%, 90%, 75%) are modeled from assumed unit economics, not observed from sales. No product has yet been built or sold.
Illustrative Revenue Mix, Third Year of Sales